- **Limited Access to healthcare:** Some communities may have limited access to quality healthcare facilities, medical professionals, or health insurance coverage, resulting in delayed or inadequate medical care.
- conditions, leading to differences in mortality and morbidity rates.
- tobacco use, contributing to varying health outcomes among different populations.

Health disparities are a complex issue and often stem from historical, societal, economic, and systemic factors2꞉

ġġƁĦƀbńŠĹ Ⅰ·ĦĀřƎⅠ· ġńbžĀƁńƎńĦb ƁĦƀƳńƁĦb ƎĀƁĹĦƎĦġ ĦĸĸŦƁƎb ĀŠġ žŦřňěńĦb ƎŦ žƁŦ ş ŦƎĦ ĦƀƳńƎY ńŠ Ⅰ·ĦĀřƎⅠ·ěĀƁĦ ĀěěĦƀb꞊ ń ş žƁŦTĦ Ⅰ·ĦĀřƎⅠ· ĦġƳěĀƎńŦŠ꞊ ĀŠġ ƁĦġƳěĦ bŦěńŦĦěŦŠŦ ş ńě ęĀƁƁńĦƁb ƎⅠ·ĀƎ ĀĸĸĦěƎ Ⅰ·ĦĀřƎⅠ· ŦƳƎěŦ ş Ħb꞊ WŦTĦƁŠ ş ĦŠƎb꞊ Ⅰ·ĦĀřƎⅠ·ěĀƁĦ ŦƁĹĀŠń2ĀƎńŦŠb꞊ ĀŠġ ěŦ ş ş ƳŠńƎńĦb ƭ ŦƁĻ ƎŦĹĦƎⅠ·ĦƁ ƎŦ ƎĀěĻřĦ ƎⅠ·ĦbĦ ġńbžĀƁńƎńĦb ĀŠġ žƁŦ ş ŦƎĦ Ⅰ·ĦĀřƎⅠ· ĦƀƳńƎY ĸŦƁ Āřř ńŠġńTńġƳĀřb꞊

> **“Clinical trial diversity plays a crucial role in addressing health disparities and promoting health equity.”**

Clinical trial diversity is crucial in addressing health disparities and promoting health equity. The inclusion of a diverse range of participants in clinical trials can have several benefits:

- **Consideration of patient representation.** By involving individuals from various racial, ethnic, gender, and socioeconomic backgrounds, clinical trials can better represent the broader population that the medical treatments or interventions will eventually serve. This ensures that the findings are applicable and effective for all groups.
- **Understand the implication of efficacy and safety of the treatment.** Different populations may respond differently to treatments due to genetic variations and other factors (e.g., social, genetic). Diverse participation in clinical trials helps identify potential differences in treatment efficacy and safety across various groups, allowing researchers to tailor treatments for specific populations.
- **Identify the disparities that exist among patients.** Clinical trials with diverse participants can help identify health disparities and underlying factors that contribute to differences in disease prevalence, progression, and outcomes among different demographic groups.
- **Ensure patient trust and engagement is paramount to addressing health disparities.** Inclusivity in clinical trials fosters trust among underrepresented communities, demonstrating that researchers value their health and well-being. This can lead to increased engagement and participation in medical research.
- **Examine how relevant policies and regulations should be applied.** Regulatory bodies often encourage or require diversity in clinical trials to ensure that treatments are thoroughly evaluated across different populations before approval and widespread use.

Enhancing our understanding of precision medicine and acknowledging the diversity of patient characteristics can contribute to a deeper comprehension of specific medical diseases and potential treatment strategies. Certain diseases have varying prevalence rates among different racial and ethnic groups. Here are some, with specific examples:

- **Hypertension:** Hypertension is more prevalent in African Americans compared to other racial groups3.
- **Diabetes:** Type 2 diabetes is more commonly seen in Native Americans, African Americans, and Hispanics. The estimated number of adults with diabetes in 2007 was 246 million; of these, 80% live in developing countries, the most significant numbers on the Indian subcontinent and in China4.
- **Sickle Cell Disease:** This genetic condition is more prevalent in individuals of African, Mediterranean, Middle Eastern, and South Asian descent5.
- **Cystic Fibrosis:** It is more common among individuals of European descent6.

It is important to note that a combination of genetic, environmental, and socioeconomic factors can influence disease prevalence. Moreover, healthcare disparities and access to medical services can also impact disease rates among different racial and ethnic groups.

III. Proposed Solution

ProPharma's novel approach as an RCO can be utilized to develop a bespoke solution to help diverse patient enrollment strategies for the sponsor's clinical trials:

Proposed Solutions

Collaboration: Collaborating with patient advocacy groups and regulatory bodies to better understand the community and address potential questions and concerns is important.	**Inclusive Outreach:** Develop marketing and outreach materials with diverse representation and language accessibility to appeal to a broader range of participants.
Community Engagement: Service organizations can engage with local communities, advocacy groups, community leaders, local medical groups/providers, non-profit organizations, etc.	**Inclusivity in Inclusion/Exclusion Criteria:** Revisiting and challenging the design of inclusion/exclusion criteria to be more inclusive of diverse patient profiles can expand the patient pool.
Cultural Competence: Ensuring that study staff have been trained in cultural competency, are culturally competent, and are sensitive to the needs of diverse patients can improve enrollment.	**Incentives and Compensation:** Offering reasonable incentives and compensation for participation can spur interest and reduce barriers.
Data Collection and Analysis: Collecting and analyzing data on demographics and patient characteristics can help identify areas for improvement. Be transparent about how data will be used and protected, addressing concerns about privacy and misuse.	**Language Accessibility:** Providing patient-facing study materials (e.g., informed consent forms and patient surveys) and interpreters in multiple languages can remove language barriers.

Proposed Solutions

Diversity in Trial Leadership: Having diverse trial leadership and research teams can inspire confidence in potential participants.

Patient-Centric Approach: Designing studies with a patient-centric approach, considering the unique needs and preferences of diverse populations.

Feedback Mechanisms: Establish accessible mechanisms for participants to provide feedback and voice concerns, ensuring they feel heard and valued.

Patient Education: Providing educational materials about clinical trials tailored to specific communities can educate, demystify, and address misconceptions. Ensuring the images and language used represent and connect to the community and not a single demographic.

Flexible & Inclusive Clinical Trial Design: Flexible trial designs, such as adaptive trials, can accommodate varying patient needs. Having relevant tools for patients, e.g., Dermatology trials- Ensure screening for melanomas or skin reactions are assessed across various skin tones.

Regulatory Compliance: Ensuring compliance with regulatory guidelines regarding diversity in clinical trials is essential.

Follow-Up: Share primary outcomes, next steps, or milestones of the clinical trial with the participants for transparency and awareness.

Site Selection: Choosing trial sites in diverse geographic locations with access to a broad patient population can enhance diversity.

By implementing some or all of the above strategies, ProPharma can contribute to more inclusive and diverse patient enrollment in clinical trials, improving the generalizability of study results and healthcare outcomes for all populations. Solutions to overcome the barriers to recruiting and retaining patients from minority populations in clinical trials require thoughtful strategies to address the obstacles and build trust.

IV. Implementation

In addition to the proposed solutions, we have many technology offerings at our fingertips to help mitigate the need for more diversity in clinical trials.

ProPharma utilizes an internal AI (Artificial Intelligence) platform that collates information from various sources and pairs them with a patient identifier to outline diversity attributes such as race and ethnicity, socioeconomic information, and education level.

These patients are then linked to specific centers and Investigators, which provide an output of where various populations can be found. While the tool offers directional guidance for what sites may be solid fits for which clinical trials, it gives the opportunity for robust feasibility studies to confirm patient availabilities.

> **“We have technology at our fingertips to assist in mitigating the lack of diversity in clinical trials.”**

An RCO ensuring diversity in clinical trials is crucial to generalize results, identify variations in treatment response, and promote ethical and equitable access to healthcare innovations. AI tools access billions of procedure codes and more than three million diagnosis codes, representing approximately 200 million patients annually. By pooling claims data and summarizing trends of specific demographic information, AI provides a deeper lens into the types of patients that require care for particular indications that may vary by gender and race; we can be better informed about where optical locations are for clinical trials to be conducted.

One strong use of AI is to provide directional guidance for the pre-identification of potential subjects, which helps to best identify the most promising sites that can deliver a clinical trial. This added layer of intelligence is critical for ensuring diverse patient populations are more readily identified and the benefits from the potential investigational treatments and the therapies clinical trials may offer are realized.

V. Conclusion

In summary, diverse patient populations must be enrolled in clinical trials. Addressing the lack of diversity in clinical trials is not just a matter of social equity but a fundamental necessity for advancing healthcare and ensuring that medical treatments are effective and safe for all individuals. As several known contributing factors may limit the lack of diversity, Sponsors, RCOs, and CROs (Contract Research Organizations) must prioritize the operational strategy of ensuring underrepresented populations are included in trials, and the strategies for developing best practices from lessons learned via historical experience. These strategies must become the new norm.

The lessons learned from the inadequate patient population in current and past clinical trials range from increasing health disparities amongst racial groups to improving drug efficacy and safety variability across all

individuals.

The proposed strategies and technological advancements highlighted in this paper provide a path forward to a future where healthcare innovations benefit everyone regardless of race, ethnicity, socioeconomic status, or cultural background. By implementing these measures, we can move closer to a world where health disparities are reduced and healthcare truly becomes accessible and effective for everyone.

References Cited

1. Fisher, J. A., & Kalbaugh, C. A. (2011). Challenging assumptions about minority participation in US clinical research. American Journal of Public Health, 101(12), 2217-2222. https://doi.org/10.2105/AJPH.2011.300279
2. National Institute on Minority Health and Health Disparities. (n.d.). Diversity and inclusion in clinical trials. https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html
3. Haiman, C. A., Chen, G. K., Vachon, C. M., Canzian, F., Dunning, A., Millikan, R. C., ... & Kolonel, L. N. (2011). A common variant at the TERT-CLPTM1L locus is associated with estrogen negative receptor–negative breast cancer. Nature Genetics, 43(12), 1210-1214. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108512/
4. Ramachandran, A., & Snehalatha, C. (2009). Current scenario of diabetes in India. Journal of Diabetes, 1(1), 18-28. https://onlinelibrary.wiley.com/doi/10.1111/j.1753-0407.2008.00004.x
5. Centers for Disease Control and Prevention. (2020, August 31). Data & Statistics on Sickle Cell Disease. [https://www.cdc.gov/ncbddd/sicklecell/data.html]
6. MedlinePlus. (2021, September 7). Cystic fibrosis. [https://medlineplus.gov/genetics/condition/cystic-fibrosis/]
7. U.S. Food and Drug Administration. (2021, June 25). FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. [https://www.fda.gov/media/157635/download]